CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $159.41 Consensus Price Target from Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have received a consensus recommendation of “Buy” from the twenty-one analysts that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $159.41.

A number of research firms have issued reports on CRSP. Citigroup upgraded CRISPR Therapeutics from a “sell” rating to a “neutral” rating and increased their price target for the stock from $55.00 to $132.00 in a report on Monday, June 14th. Canaccord Genuity increased their target price on CRISPR Therapeutics from $151.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, August 16th. TheStreet upgraded CRISPR Therapeutics from a “d” rating to a “c+” rating in a report on Monday, August 9th. Chardan Capital dropped their price objective on CRISPR Therapeutics from $175.00 to $171.00 and set a “buy” rating on the stock in a research note on Friday, July 30th. Finally, upgraded CRISPR Therapeutics from a “sell” rating to a “neutral” rating and raised their price objective for the company from $55.00 to $132.00 in a research note on Monday, June 14th.

Shares of CRISPR Therapeutics stock traded up $0.56 during trading on Wednesday, reaching $117.81. The company’s stock had a trading volume of 658,407 shares, compared to its average volume of 1,630,672. The business’s 50-day moving average price is $123.69 and its 200-day moving average price is $124.19. The firm has a market cap of $8.98 billion, a PE ratio of 22.95 and a beta of 2.25. CRISPR Therapeutics has a 52 week low of $79.31 and a 52 week high of $220.20.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Thursday, July 29th. The company reported $9.44 EPS for the quarter, topping analysts’ consensus estimates of $3.52 by $5.92. CRISPR Therapeutics had a net margin of 49.52% and a return on equity of 24.08%. The firm had revenue of $900.70 million during the quarter, compared to analysts’ expectations of $678.05 million. On average, equities analysts forecast that CRISPR Therapeutics will post 4.81 EPS for the current year.

In other CRISPR Therapeutics news, CFO Michael John Tomsicek sold 25,000 shares of CRISPR Therapeutics stock in a transaction dated Friday, August 6th. The stock was sold at an average price of $138.52, for a total transaction of $3,463,000.00. Following the completion of the transaction, the chief financial officer now owns 26,891 shares of the company’s stock, valued at approximately $3,724,941.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 1,500 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, August 4th. The shares were sold at an average price of $125.02, for a total value of $187,530.00. Following the sale, the chief executive officer now owns 189,219 shares of the company’s stock, valued at approximately $23,656,159.38. The disclosure for this sale can be found here. In the last three months, insiders sold 81,875 shares of company stock valued at $12,146,610. 10.70% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Abundance Wealth Counselors bought a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at about $26,000. Tradition Wealth Management LLC bought a new stake in CRISPR Therapeutics in the 2nd quarter worth approximately $26,000. Arkadios Wealth Advisors bought a new stake in CRISPR Therapeutics in the 2nd quarter worth approximately $27,000. RMR Wealth Builders bought a new stake in CRISPR Therapeutics in the 1st quarter worth approximately $29,000. Finally, Ameritas Investment Company LLC bought a new stake in CRISPR Therapeutics in the 1st quarter worth approximately $29,000. Hedge funds and other institutional investors own 52.68% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

Recommended Story: Debt-To-Equity Ratio

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.